Audit: QRS - Pregnenolone for Health & Longevity
Audit conducted on 12/09/2026 04:09 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every protocol cell, gate item, tier item, marker row and cadence string traces to a named ER passage. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No independently validated target”, “unmeasured hormonal effects” and “the age-decline premise is contested” mirror the ER’s hedging. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications stay absolute; interactions stay cautionary; no tier is upgraded or downgraded. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Stop items come only from “Populations who should avoid Pregnenolone”, caution items only from the interaction bullets, risk tiers only from Potential Risks & Side Effects. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, author names, NCT numbers or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution appears anywhere in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, qualified register of the ER Conclusion is carried through verbatim in places. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Dose, timing, monitoring targets and stop thresholds give the reader actionable structure without overselling. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as observed practice and measured findings, not as instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative addressed to a patient; gate and monitoring content is descriptive. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “advised” or “should” constructions in the QRS’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun appears in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Jargon is expanded or avoided; “prostate-specific antigen”, “sex hormone-binding globulin” and “thyroid-stimulating hormone” are spelled out rather than abbreviated. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items, tier items and marker cells are trimmed to the key fact; the ER’s Context/Notes column is dropped entirely. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed across header, at-a-glance, protocol, gates, cards and footer. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes lab access, baseline panels and a numeric symptom score. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | A ten-marker hormone panel, weekly blood pressure and annual prostate-specific antigen are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Demands of the monitoring and titration content exceed general-population expectations. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance leads with the fact that no study tested undiagnosed adults — the decisive point for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Route of administration is given as “Oral, once daily” (action_1_sub); no “pill”, “taken by mouth” or similar appears. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate headings, tier labels and the three column headers match the template byte-for-byte. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | page_title, header_, at_a_glance, action_1–3_, time_1–3*, benefits, stop_items, caution_items, risks_, marker_#*, monitoring_cadence and qualitative_item# are all present. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans (website="evidence_review", website="audit", website="full_review") are carried over unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the Risks High tier carries explanatory prose rather than an empty-state phrase, and is handled under 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels (“Standard supplement protocol”, “Best time of day”, “Low dose may outperform high dose”) and all nine interaction labels are reproduced verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names match the ER Biomarker column exactly, including “Prostate-specific antigen (men 40 and over)”. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | The ER’s 🟩/🟥/🟨/⚠️/⭕️ markers are all stripped; tiering is conveyed by bold labels and CSS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: the monitoring Context/Notes column is dropped, marker targets are trimmed, and tier items are reduced to bare headings. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; it is the first element after the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no value is echoed into the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: pregnenolone_2026-0912-0012_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0912-0353. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” carries no trailing qualifier such as a context-window marker. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Pregnenolone for Health & Longevity - Quick Reference Sheet” with the ampersand correctly encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Pregnenolone for Health & Longevity”, matching the ER frontmatter canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0912-0353 renders as “09/12/2026”. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four sentences compress the Conclusion’s pathway framing, benefit list, evidence gaps and harms. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a separate sentence of the ER Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronym or clinical-register term; “overstimulation”, “sleep disruption” and “supplement labels” are lay-transparent. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, n or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | “small trials” and “doses far above supplement labels” are qualitative, not statistical. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items come from the “Populations who should avoid Pregnenolone” list and the abiraterone bullet in that section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER bullets are represented; the first is split into the cancer-history item and the prostate-specific antigen threshold item. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes or trailing clauses; the ER’s gloss “(extra beats arising in the heart’s lower chambers)” is dropped as explanatory. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(any stage)”, the 4 ng/mL and 0.75 ng/mL per year thresholds, “pending urological assessment”, “(any gestational age)” and “causing heavy bleeding” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names seven such populations, and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items come from the interaction bullets of that section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine of the ER’s ten interaction bullets appear; the steroidogenesis-inhibitor bullet is correctly omitted because abiraterone is listed as a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The corticosteroid bullet’s em-dash gloss “— steroid drugs given to damp inflammation…” is stripped; no mitigation text or citation is carried over. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every named drug list is retained, including “(diazepam, lorazepam, zolpidem)” and “(caffeine, Rhodiola rosea, tyrosine)” with the italics preserved as <em>. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten interactions, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from bullets in Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and the dose-response caveat are the three decision-bearing bullets; the remaining bullets are background or modifiers. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | “5–50 mg daily”, “Morning” and “30 mg over 200 mg” with their subs all trace to the ER bullets of the same names. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Craving/anxiety, chronic low back pain and psychiatric/cognitive change are the three windows named in the ER’s “Time to effect” bullet. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High (craving), Medium (back pain), then the psychiatric/cognitive cluster, matching the ER benefit tiers. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names three distinct windows; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “Within 2 weeks”, “4 weeks” and “8–12 weeks” with their subs are drawn from the ER’s Practical Considerations time-to-effect bullet. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All twelve items correspond one-to-one with the ER’s benefit headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; no Magnitude text, p-value or source is carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content remains in any benefit tier. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers contain items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eight items correspond one-to-one with the ER’s risk headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present; risks_high is retained and hidden. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; counts such as “5 versus 0” and the ⚠️ Conflicted marker are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content remains in any risk tier. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER states “No risk reaches High”, and risks_high carries style="display: none" with no empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence derive from Monitoring Protocol & Defining Success. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten rows of the ER biomarker table are present, in ER order, with Optimal Functional Range and Why Measure It mapped to Target and Why. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Baseline, 8–12 weeks, 6-monthly, weekly/monthly vitals and annual prostate-specific antigen all match the ER’s ongoing-monitoring paragraph. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Taken from the ER’s “Qualitative markers worth tracking alongside the labs” list. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All nine ER qualitative markers appear verbatim and in ER order. |
Issues 12/09/2026 04:09
Pass rate 100.00%. No issues found.
Issues 12/09/2026 04:03
- 8.5 — PSA qualifier dropped: The contraindication “Men with prostate-specific antigen above 4 ng/mL or a rise over 0.75 ng/mL per year” (line 575) omits the ER’s qualifier “pending urological assessment” (ER line 333), which defines the contraindication as a deferral rather than a permanent bar.
Fixes 12/09/2026 04:03
- 8.5 — PSA qualifier restored: Appended the ER’s dropped qualifier to the prostate-specific antigen contraindication, changing it from “…or a rise over 0.75 ng/mL per year” to “…or a rise over 0.75 ng/mL per year, pending urological assessment”.
Issues 12/09/2026 03:58
- 7.2 — At-a-glance exceeds word cap: The [at_a_glance] span (lines 433–439) contains 62 words, two over the 60-word maximum.
Fixes 12/09/2026 03:58
- 7.2 — At-a-glance trimmed under word cap: Condensed [at_a_glance] from 62 to 59 words by dropping “Human” before “benefits” and replacing “adults without a diagnosis” with “undiagnosed adults”; all ER-supported facts retained.